Enantioselective Synthesis of OBI-3424 Prodrug
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current cancer treatments face challenges in selectively targeting cancer cells without damaging normal cells, leading to adverse side effects and limiting the dosage of anti-cancer drugs.
Innovation Solution
The synthesis and identification of the anti-cancer small molecule prodrug OBI-3424, which involves specific chemical reactions using compounds like BH3, B-Chlorodiisopinocampheylborane, and lipase or protease enzymes to achieve high optical purity and selectivity.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional cancer treatments are used, then anti-cancer effect is achieved, but normal cells are damaged causing adverse side effects
Solution Approach 1:
The patent applies local quality by designing a prodrug with specific stereochemical configuration (enantiomeric excess ≥90%) that is selectively activated by AKR1C3 enzyme overexpressed in cancer cells. The chiral purity ensures the drug interacts specifically with cancer cell targets while sparing normal cells, achieving localized therapeutic effect at the molecular level.
Solution Approach 2:
The patent utilizes parameter changes by controlling the enantiomeric excess to be no less than 90%, which optimizes the drug's interaction with AKR1C3 enzyme. This specific stereochemical parameter enhancement improves selective activation in cancer cells while reducing off-target effects on normal cells.
2Reliability
If high dosage of anti-cancer drug is administered, then treatment efficacy is improved, but adverse side effects increase
Solution Approach 1:
The patent employs preliminary action by designing a prodrug that requires enzymatic activation by AKR1C3 before becoming therapeutically active. The inactive prodrug form can be administered at higher doses without immediate toxicity, and is then selectively converted to the active form in cancer cells, achieving high efficacy without proportional increase in side effects.
3Manufacturing precision
If enantioselective synthesis is performed to achieve high optical purity, then drug selectivity is improved, but manufacturing complexity increases
Solution Approach 1:
The patent applies preliminary action by using chiral auxiliaries or catalysts in the synthesis process to pre-establish the desired stereochemistry before the final product formation. This approach (exemplified by CBS reduction or enzymatic kinetic resolution) ensures high enantiomeric excess (≥90%) is achieved during synthesis rather than requiring complex post-synthesis separation processes.
Solution Approach 2:
The patent replaces mechanical separation methods with enzymatic kinetic resolution using lipases or proteases. This biochemical approach (principle 28) substitutes complex mechanical chiral separation equipment with biocatalytic processes that naturally distinguish between enantiomers, simplifying the manufacturing process while achieving ≥90% enantiomeric excess.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The method enables the effective synthesis of OBI-3424 with high optical purity, potentially enhancing cancer treatment by selectively targeting cancer cells while minimizing harm to normal cells, thus improving treatment efficacy and reducing side effects.
Implementation Method 1
reacting a compound of Formula 2 with a compound of Formula 3a in the presence of BH3, B-Chlorodiisopinocampheylborane (DIP-Chloride), (S)-(−)-1,1′-Bi-2-naphthol, or NaBH4
Implementation Method 2
reacting a product of step (1) with: (A) lipase acrylic resin, Na2CO3, and one of isopropenyl acetate and 2,2,2-trifluoroethyl butyrate; or (B) protease, Na2CO3, and one of isopropenyl acetate and 2,2,2-trifluoroethyl butyrate
Data Source
AI summary
A new process to synthesis of compound OBI-3424 R-form and S-form products is provided. The “R-form” compound OBI-3423 was first synthesized with 48% overall yield from compound OBI-3424-5 by installation of the labile phosphate motif at later stage. The stereo chemistry is established by 5 steps chemo-enzyme combination synthesis to afford 99% optical purity. After then, the “S-form” compound OBI-3424 is prepared with improving overall yield of 54% from compound OBI-3424-5. The stereo chemistry is established by 4 steps combination of chemo-enzyme synthesis with excellent optical purity of 99%.